Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.
For Casey Means, American medicine wasn't a career—it was a problem to solve. The Senate isn't so sure she's the solution.
Onlymyhealth on MSN
Continuous Glucose Monitors (CGM): Should Non-Diabetics Wear Them? Expert Explains
Continuous Glucose Monitors (CGMs) were once considered medical devices strictly meant for people living with diabetes.
Ultra-low-power TMR switches enable reliable CGM activation by minimizing energy consumption while maintaining accurate, ...
The Helsinki‑based company offers AI-enabled biometric and gesture recognition technology that allows for device control with ...
In combining the precision of the twiist insulin delivery system with the unmatched longevity of Eversense 365, Sequel and Senseonics are enhancing diabetes management by offering more tools to manage ...
March 5 (Reuters) - MiniMed, the diabetes business of medical device maker Medtronic, said on Thursday it has raised $560 ...
Senseonics' Eversense 365 drives 72% Q4 growth as company reclaims U.S. commercialization and targets 65-76% revenue increase ...
MiniMed (MMED) shares drop 4.8% in Nasdaq debut, opening at $19.05 after raising $560M in IPO. Medtronic (MDT) retains 90% stake in diabetes device spinoff.
Medtronic broadens its diabetes device portfolio with MiniMed Go Smart MDI system launch across Europe The integrated ...
The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.
DexCom, Inc. (DXCM) 47th Annual Raymond James Institutional Investor Conference March 2, 2026 1:05 PM ESTCompany ParticipantsJereme Sylvain - Executive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results